UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress‐mediated apoptosis

UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP

(2019) Dian Jiao et al.   ONCOGENE

Retinoblastoma, the visible CNS tumor: A review

(2018) Helen Dimaras et al.   JOURNAL OF NEUROSCIENCE RESEARCH

UHRF1 depletion sensitizes retinoblastoma cells to chemotherapeutic drugs via downregulation of XRCC4

(2018) Heng He et al.   Cell Death & Disease

Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells

(2018) Francis O. Enane et al.   Cell Death & Disease

The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat

(2017) Chiara Zagni et al.   MEDICINAL RESEARCH REVIEWS

Functional dissection of the role of UHRF1 in the regulation of retinoblastoma methylome

(2017) Guangyan Kan et al.   Oncotarget

Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia

(2016) Elena Ceccacci et al.   BRITISH JOURNAL OF CANCER

Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma

(2016) Eleanor M. Pritchard et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

A review of the literature for intra-arterial chemotherapy used to treat retinoblastoma

(2016) Emily Wyse et al.   PEDIATRIC RADIOLOGY

Establishment of a novel retinoblastoma (Rb) nude mouse model by intravitreal injection of human Rb Y79 cells – comparison ofin vivoanalysis versus histological follow up

(2016) Alexander V. Tschulakow et al.   Biology Open

Sp3/REST/HDAC1/HDAC2 Complex Represses and Sp1/HIF-1/p300 Complex Activates ncx1 Gene Transcription, in Brain Ischemia and in Ischemic Brain Preconditioning, by Epigenetic Mechanism

(2015) L. Formisano et al.   JOURNAL OF NEUROSCIENCE

Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression

(2015) Claudia A. Benavente et al.   Oncotarget

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

(2014) M. Bots et al.   BLOOD

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release

(2014) Dmitry B. Zorov et al.   PHYSIOLOGICAL REVIEWS

Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis

(2013) Christian Bronner et al.   BIOCHEMICAL PHARMACOLOGY

A Histopathologic Analysis of Eyes Primarily Enucleated for Advanced Intraocular Retinoblastoma From a Developing Country

(2012) Seema Kashyap et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies

(2012) Yogen Saunthararajah et al.   SEMINARS IN ONCOLOGY

Coexpression of Normally Incompatible Developmental Pathways in Retinoblastoma Genesis

(2011) Justina McEvoy et al.   CANCER CELL

Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers

(2010) Motoko Unoki   Recent Patents on Anti-Cancer Drug Discovery

Retinoblastoma Has Properties of a Cone Precursor Tumor and Depends Upon Cone-Specific MDM2 Signaling

(2009) Xiaoliang L. Xu et al.   CELL

Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma

(2008) C. L. Dalgard et al.   CLINICAL CANCER RESEARCH

UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells

(2008) Jong Kyong Kim et al.   NUCLEIC ACIDS RESEARCH